Single dose palonosetron and dexamethasone in preventing nausea and vomiting induced by high emetogenic ABVD regimen in Hodgkin Lymphoma patients |
| |
Authors: | Rigacci Luigi Landi Carla Caruso Jean Pierre Puccini Benedetta Alterini Renato Carrai Valentina Perrone Tania Bosi Alberto |
| |
Affiliation: | Haematology Department, Azienda Ospedaliero Universitaria Careggi, Largo Brambilla, 3 50139 Firenze, Italy. luigi.rigacci@unifi.it |
| |
Abstract: | To evaluate the efficacy of a new agent, palonosetron, in Hodgkin Lymphoma patients treated with ABVD regimen. Complete response during the overall phase of the first ABVD cycle, was the primary endpoint. Secondary end points were: emesis-free patients and use of rescue medication during the acute and overall phases. From January 2008 to February 2009 36 patients were enrolled. The primary endpoint (CR 0-120 h) was achieved by 55.6% patients. In conclusion our study demonstrated that a single dose of palonosetron plus a single dose of dexamethasone was effective in preventing CINV in patients treated with ABVD regimen. |
| |
Keywords: | |
本文献已被 PubMed 等数据库收录! |
|